Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)

Table 2 Patient-reported outcomes by BTA treatment and risk status

	Patients treated with BTA therapy			Patients not treated with BTA therapy				High bone complication risk			Low bone complication risk
	N	Mean	SD	N	Mean	SD	p value³	N	Mean	SD	N	Mean	SD	p value³
Pain (BPI-SF)^a
Worst pain	296	3.1	2.9	104	2.5	2.7	0.076	229	3.0	2.9	155	2.9	2.7	0.684
Least pain	295	1.2	1.6	104	1.1	1.6	0.815	228	1.1	1.6	155	1.2	1.6	0.364
Average pain	296	2.1	2.1	104	1.9	2.1	0.249	229	2.1	2.1	155	2.0	2.0	0.957
Pain right now	296	1.7	2.2	104	1.4	1.9	0.359	229	1.5	2.1	155	1.7	2.1	0.414
Bone pain (FACT-BP)^b	301	47.7	12.4	105	50.7	11.0	0.007	230	48.1	12.1	160	48.9	11.9	0.397
Quality of Life (FACT-G)^b
Physical wellbeing	302	20.5	5.7	105	21.5	5.4	0.084	231	20.6	5.8	160	20.8	5.6	0.693
Social/family wellbeing	299	21.7	5.0	105	22.6	4.8	0.101	231	21.9	5.0	158	22.0	4.8	0.961
Emotional wellbeing	300	17.4	4.7	105	18.5	4.2	0.060	231	17.7	4.7	158	17.6	4.5	0.698
Functional wellbeing	303	17.8	5.4	105	18.9	5.2	0.078	232	17.7	5.5	160	18.5	5.0	0.205
FACT-G total score	296	77.4	15.5	105	81.4	14.4	0.031	229	78.1	15.4	157	78.8	15.5	0.665

ISSN: 1471-2407